{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Overall response rate (ORR) was defined as the percentage of participants who achieved an Investigator-determined best overall response (BOR) of partial response (PR) or complete response (CR) as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants who achieved ORR were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-small cell lung cancer received selinexor 60 mg orally QW and docetaxel 75 mg/m\\^2 IV for every 3 weeks until PD or intolerable toxicity.","id":"OG000","title":"Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel"},{"description":"Participants with colorectal cancer received selinexor 80 mg orally QW and pembrolizumab 200 mg IV every 3 weeks until PD or intolerable toxicity.","id":"OG001","title":"Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-treat (MITT) population for the combination period included all participants who received at least 1 dose of selinexor in the combination therapy period.","reportingStatus":"POSTED","timeFrame":"Up to 25 months","title":"Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}